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Lung cancer is a disease with a high mortality rate for the U.S. Black population. There 
had been considerable research done on different population demographics, necessary to 
achieve the Healthy People 2020 overarching goals to eliminate health disparities, gain 
health equity and maintain quality health. Yet, the African-born Black (AFBB) 
population has been understudied for nonsmall cell lung cancer (NSCLC). This study 
sought to determine whether within race differences in stage at diagnosis and treatment of 
NSCLC exists between AFBB and American-born Blacks (AMBB) populations in the 
United States. The study data is secondary data collected as part of the National Cancer 
Institute’s Surveillance Epidemiologic and End Result (SEER) Program from 2004-2011. 
Athough no significant difference was found between AFBB (n = 119) and AMBB (n = 
238) relative to NSCLC stage at diagnosis, differences in treatments were found. The 
proportion of AFBB patients with early stage (I and II) NSCLC who underwent surgery 
differed significantly from that of AMBB (p < 0.05); AFBB patients were more likely to 
receive surgical therapy. The proportion of AFBB patients with stages I-IV of the disease 
who received radiation treatment also differed significantly from that of AMBB patients 
(p < 0.05); the latter were more likely to receive radiation therapy. Results from logistic 
regression analysis indicate that AFBB patients were more likely to receive surgical 
treatment while AMBB patients were more likely to receive radiation treatment. This 
study outcome can inform other NSCLC research to provide better insights to the cause 
of the treatment differences within the race from differing birth places, and efficient 
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Chapter 1: Introduction to the Study  
Problem Statement   
According to the National Cancer Institute (2013f), U.S. Whites and Blacks have 
marked disparities when it comes to cancer incidence and mortality. The Black 
population has higher incidence and mortality rates. According to the United States 
Census Bureau (2012), the Black race in the United States constitutes people born in the 
United States as well as immigrants. This means that the U.S Black population is 
heterogeneous in terms of place of birth.  
Yet, cancer racial comparison from National Cancer Institute (2013f) does not 
stratify the Black population by place of birth to determine within-race differences in 
disease epidemiology that might exist. African-born Black (AFBB) immigrants constitute 
part of the Black race population (United States Census Bureau, 2012) and are considered 
in the comparative analyses between Blacks and Whites. Their population grew by 200% 
from the 1980s through the 1990s, then by 100% from then through the 2000s to a total 
of 1.1 million due to admission of large number of African refugees and the introduction 
of the diversity visa program by the U.S. government (Capps, McCabe, & Fix, 2011). 
Therefore, knowledge of the AFBB lung cancer epidemiology as compared to their 
American-born Black (AMBB) counterpart will be of importance in effective planning, 
management and evaluation of control programs of the disease for this population. 
According to global cancer statistics for 2008, lung cancer was the most common 
among all cancers for both males and females, accounting for approximately 12.7% of all 
the cancers and 18.2% of cancer related mortalities (Ferlay et al., 2010). For males, lung 
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cancer was the most common type of cancer and cancer-related mortality, with an age-
standardized incidence rate of 34.0 per 100,000 population members and an age 
standardized mortality rate of 29.4 per 100,000 population members (Ferlay et al., 2010). 
For females, lung cancer was the fourth most common type of cancer behind breast, 
colorectal, and cervical cancers. A comparison of lung cancer incidence and mortality 
rates by world region showed that the age-standardized incidence rate was 13.5 per 
100,000 population members, and the age standardized mortality rate was 11 per 100,000 
population members (Ferlay, et al, 2010). 
 In addition to sex, incidence and mortality rates for lung cancer differ by 
geographic region and race. According to Ferlay et al. (2010), the Middle African region 
had the lowest age-adjusted incidence rates for lung cancer among all African regions 
with 2.8 for males and 0.9 for females (per 100,000 population members), followed by 
the Western African region with 3.1 for males and 1.2 for females. The Middle African 
region  also had the lowest age-adjusted mortality rates for the disease with 2.7 for males 
and 0.8 for females (per 100,000 population members), followed by Western Africa with 
2.9 for males and 1.1 for females (Ferlay et al., 2010; Figure 6). Meanwhile, North 
America had the highest age-adjusted incidence rates for lung cancer with 48.5 per 
100,000 population members for males and 35.8 per 100,000 population members for 
females (Ferlay et al., 2010).  The U. S. continent also had the highest age-adjusted 
mortality rate from the disease with 37.9 deaths per 100,000 population members for 
males and 24.2 deaths per 100,000 population members for females (Ferlay et al., 2010; 
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Figure 6).  This 2008 worldwide cancer statistics show that lung cancer is widely 
distributed with incidence and mortality rates varying from region to region.  
 Analyzing data for 2001-2010, researchers at the National Cancer Institute 
(2013f) reported racial and gender differences in lung cancer incidence and mortality 
rates among the U.S. population. Investigators observed a higher incidence of lung cancer 
among males (74.3 cases per 100,000 population members) than among females (51.9 
cases per 100,000 population members). Meanwhile, the mortality rates per 100,000 
population members for males of all races were 63.5; for females, it was 39.2. The 
National Cancer Institute also observed gender differences for the disease within race. 
Among U.S. Black males, the incidence rate per 100,000 population members was 95.8; 
for Black females, it was 52.2. The National Cancer Institute (2013f) report shows that 
the mortality rate per 100,000 population members for Black males was 78.5 while for 
Black  females was 37.2. This finding also shows lung cancer racial trends where the 
incidence rate per 100,000 population members for both sexes for Whites was 63.1 and 
for Blacks was 69.7 while the mortality rates per 100,000 population members for Whites 
was 50.2 and for Blacks was 53.5 (National Cancer Institute, 2013f). Overall, from 2001-
2010 in the United States, while the incidence rate for lung cancer for Black males was 
almost double that for Black females; the mortality rate for Black males was more than 
double that for Black females. Mortality rates for Black patients at late stage nonsmall 
cell lung cancer (NSCLC) was higher than that for White patients in a study carried out 
by Hardy, Xia, Liu, Cormier, Nurgalieva, and Du (2009). Yet they showed that for both 
black and white patients the mortality rates were significantly reduced when stage 
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specific standard therapies were received. Their study outcome underscores the 
importance of comparing the incidence, mortality rates, treatments, and outcomes for 
lung cancer among similar groups. 
Risk Factors for lung cancer. Risk factors for lung cancer incidence. The risk factors 
for lung cancer even among people of the same race have been shown to vary depending 
on several factors. Etzel et al. (2008) studied lung cancer risks among African Americans 
and found that exposure to air pollutants that include tobacco smoke, asbestos, wood 
dusts, toluene, and xylene increased the risk for developing the disease. The researchers 
found that lung cancer risk increased with duration and quantity of the tobacco smoke 
exposure and the age of the individual as well as preexisting conditions such as chronic 
obstructive pulmonary disease (COPD). Individuals with preexisting diseases such as 
AIDS with recurrent pneumonia, and pulmonary tuberculosis, are two to five times more 
likely to develop lung cancer than the general population (Shebl, Engels, Goedert, & 
Chaturvedi, 2010; Hou, Fu, Ge, Du, & Hua, 2013).  
The impact of differing early life experiences to lung cancer health has been 
studied and documented. Early life exposure to second-hand tobacco smoke increases the 
risk for lung cancer (Brown Anda, Felitti, Edwards, Malacher, Croft, & Giles, 2010). 
Also, the burning of biomass or solid fuel for cooking, which is most common in 
developing nations (Bonjour, et al. 2013), is a risk for lung cancer as it releases and 
exposes the household to particulate matter and CO2 at a daily concentration that is 
comparable to those of active cigarette smokers (Pope et al., 2009, 2011; Smith et al., 
2010). Indoor radon and workplace chemical carcinogens contribute to about 25% of all 
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lung cancer cases and about 300,000 lung cancer deaths worldwide (Youlden, Cramb, & 
Baade, 2008). Therefore, exposure to certain airborne pollutants is a risk for developing 
lung cancer. 
Lung cancer etiology and mortality perceptions and beliefs differ by race. Here, 
the likelihood of Black Americans race to hold a belief that would interfere with the 
prevention and treatment of lung cancer is higher than that of  White Americans, OR = 
2.05, 95% CI [1.19-3.53] (Lathan, Okechukwu, Drake, and Bennett,2010). The Black 
American race would more likely avoid lung cancer disease screening and evaluation due 
to the fear that they will be diagnosed with the disease. 
  
Risk factors for lung cancer mortality. Lung cancer mortality rate is influenced 
by several factors. Lung cancer at its earlier stage is asymptomatic, but, gradually, those 
with the disease develop symptoms that are nonspecific, thus masking the cancer which 
would be later diagnosed at an advanced stage of development (Youlden, et al., 2008). 
Diagnosis at a late stage of the disease is the primary reason for the low survival high 
mortality rates (Youlden, et al., 2008). Nonspecific symptoms coupled with lack of 
adequate and qualified diagnostic health care personnel and tools contribute to late stage 
diagnosis and impact the disease prognosis (Youlden, et al., 2008).  
The class and stage of lung cancer which constitute the outcome variable in this 
study is obtained through what is known as the tumor, node, metastasis staging, primarily 
by the technique called computer tomography and positron emission tomography  scans 
(Mirsadraee, Oswal, Alizadeh, Caulo, & van-Beek, 2012). Furthermore, this staging 
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process provides the extension of the tumor anatomy, from which the disease prognosis 
and therapy are based. The two major forms of the disease are the small-cell lung cancer 
(SCLC), and the NSCLC (Mirsadraee et al., 2012).  While SCLC is the more aggressive 
or highly metastatic form, NSCLC is of higher incidence and less aggressive consisting 
of three subtypes.  The three subtypes for the NSCLC are: adenocarcinoma that is often 
found in the pleura or outer area of the lung; squamous cell carcinoma which forms in the 
center of the lung by the bronchi; and the large cell carcinoma, which is the fastest 
growing of the three subtypes, and usually forms indiscriminately in any part of the lung. 
Lung cancer prognosis is very poor when it is diagnosed at an advance stage than when 
diagnosed at an earlier stage. Differences in health insurance have been shown to affect 
lung cancer diagnosis and care in which case  the unavailability or inadequate health 
insurance policies influence lung cancer mortality (Bradley, Dahman, & Given, 2008). 
Studies examining risk factors have shown that high mortality rates in Blacks as 
compared to Whites diminish after controlling for health insurance type (Elchoufaniz, et 
al, 2013). Thus, The reasons for late stage diagnosis have been linked to several factors 
that include socioeconomic status, culture, health beliefs, and preexisting lung diseases 
confounding the symptoms. 
 African Born Population Health Studies. Health studies with African 
population had been overwhelmingly involved with infectious diseases such as malaria, 
tuberculosis, and HIV/AIDS, draining both resources and manpower from other disease 
studies (Galukande & Kiguli-Malwadde, 2010) providing a wealth of statistics. Such 
studies help reveal infectious diseases patterns for the African-born population, and guide 
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policies that allow for appropriate treatment of those identified as infected, and control of 
the disease. Since such intense studies have been lacking with most other chronic 
diseases among which is cancer, the pattern of cancer epidemiology in Africa as well as 
the African-born black immigrants to the U.S. is not well documented and is not well 
understood. Thus, infectious diseases stand out as the only diseases plaguing Africans. 
Claims that cancer incidence and mortality rates are high among Africans; with only 
available statistics being estimated from the limited data that are collected by the sparse 
urban services for cancer diagnosis, treatment, registry, as well as death registries which 
serve only about 8% of the total African population (Sitas et al., 2006). Data used in 
developing the cancer statistics for Africa by the International Agency for Research on 
Cancer are collected by cancer registries located in 12 countries namely; Algeria, Egypt, 
Mali, Mozambique, Nigeria, Senegal, South Africa, Gambia, Tunisia, Uganda, and 
Zimbabwe, out of the 53 African countries (International Agency for Research on 
Cancer, 2011, and United Nations, 2013a). 
U S. Cancer Registries. In the United States, the contemporary estimate of 
national cancer statistics is provided through the Surveillance, Epidemiology, and End 
Results (SEER) program. Created by the National Cancer Institute (NCI), it consists of 
18 registries located in 14 states (Alaska, Arizona, Connecticut, Michigan, Georgia, 
California, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, Washington, 
and Utah; National Cancer Institute, 2013a). Its website contains data on race, date of 
birth, sex, stage and age at diagnosis, treatment type, place of residence, marital status, 
country, and state of birth from the cancer surveillance reports for patients diagnosed 
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with cancer (National Cancer Institute, 2013d, and 2013e).These registries account for 
about 28% of the U.S. population and include 26% of its Black population. The 
population that the SEER program covers compares to the general U.S. population in 
terms of poverty and education level, and consists of a higher proportion of foreign-born 
persons (National Cancer Institute, 2013a, 2013b, 2013c). For the purpose of lowering 
cost and improving quality and consistency of data collected, all the registries are 
supported by a centralized data management system (National Cancer Institute, 2013a, 
2013b, 2013c). Thus, the U.S. centralized system of cancer registries provides a unified 
method of collecting and managing cancer data.  
African Registries. African countries participating in the World Health 
Organization (WHO) cancer data collection lack a unified authoritative cancer registry. 
Unlike the United States where all 14 participating states operate cancer registries under a 
unified central organization, SEER, those countries in Africa from which WHO gathers 
data used for world cancer statistics operate their own independent cancer registries. The 
few African countries that operate their own cancer registries are Algeria, Egypt, 
Gambia, Mali, Mozambique, Nigeria, Senegal, South Africa, Tunisia, Uganda and 
Zimbabwe (International Agency for Research on Cancer, 2011).  
Dependence on anecdotes is insufficient in determining how lung cancer 
epidemiology for the African-born Black subgroup compares with the American-born 
Black subgroup. Most health studies for population subgroups are usually unavailable 
because of the difficulties with appropriate and sufficient data collection, the cost, 
manpower and time. Cancer, including lung cancer data for the African-born Blacks in 
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the U.S is readily available through the SEER program and is used only when considered 
in African American cancer epidemiologic studies. The data include variables such as 
cases’ race, sex, age, place of birth, and type, stage and date of cancer diagnosis, 
treatment type received as well as the disease outcome (National Cancer Institute, 2013d, 
and 2013e) that can be used to generate cancer statistics on a sample of African born 
Black population. One of the cancers showing the highest incidence and mortality 
disparity between the White and Black populations is lung cancer (National Cancer 
Institute, 2013f). It therefore gives a great opportunity to examine whether there are any 
differences in the stage at which the cancer is diagnosed and the type of treatment 
received between the Black populations of African and American nativities in the United 
States. Therefore, in this study, I seek to determine whether there is any difference in the 
stage at diagnosis and the type of treatment received for NSCLC among AFBB and 
AMBB populations in the United States.  
This type of analysis requires the disease incidence cases to serve as the 
population under study. The World Health Organization collects cancer data from 
different countries in the world using standardized methods (International Agency for 
Research on Cancer, 2013a). These data have been used to study the global epidemiology 
of cancers, including lung cancer, providing countries’ cancer incidence and mortality 
rates to the International Agency for Research on Cancer (IARC) for their GLOBOCAN  
publication (Ferlay, Shin, Bray, Forman, Mathers, & Parkin , 2010; International Agency 
for Research on Cancer, 2013b). Sources for mortality data include cancer registries, vital 
records, and verbal autopsy surveys. Then for incidence rates, the WHO obtains 
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countries’ data by: (1) high quality regional data classified in 3 alpha numeric categories 
as A, B, and C according to the percentage of the cases that it covers which are 
respectively: greater than 50%; between 10% and 50%; and lower than 10%; (2) National 
data or category D; (3) Regional data or category E; (4) Frequency data or category F; 
and (5) no data or category G. According to the type of data available, various methods 
are used to estimate each country’s incidence and mortality rates. These methods include:  
rates projection to 2012, applying most recent rates to the 2012 population, estimates 
using modelled survival, using weighted average of the local rates to estimate the national 
rate, use of data from a single cancer registry or use of the weighted average of local 
rates, and the use of neighboring countries’ rates or data to estimate another country’s 
rates (International Agency for Research on cancer, 2013b). The data source and methods 
outlined by International Agency for Research on Cancer, (2013b) indicate that data from 
the United States fall in category A and it covers more than 50% of the cancer cases;  but 
most African countries (including Angola, Burundi, Cameroon,   Cape Verde, Central 
African Republic, Chad, Congo, Democratic Republic of Congo,  Cote d Ivoire, Ethiopia, 
Gabon, Ghana, Guinea,  Guinea-Bissau, Kenya, Lesotho, Liberia, Mali, Morocco, 
Mozambique, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, Somalia, Sudan, Tanzania, 
Togo, Uganda, Western Sahara and Zambia)  fall in categories  E, F and G for which data 
availability is less than 10% or is not available at all, while the only high quality data 
from Africa come from Egypt, Uganda and Zimbabwe that fall under category C.   
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Nature of the Study  
I will use a retrospective study design using secondary data acquired from the 
SEER database, the underlying cancer data source for the study.  For this study, the 
frequency data for lung cancer from 2004-2011 for Black cases of American and African 
nativities shall be obtained from the SEER database using Black race, place of birth and 
NSCLC as filters for the specific states that operate a SEER Cancer Registry. The queried 
data shall be edited to make sure that only patients with information that include the age, 
gender, the NSCLC stage at diagnosis, treatment type as radiation and surgery, shall be 
selected for the study.  The Statistical Packages for the Social Sciences (SPSS) or the Epi 
Info software shall use to perform the necessary data analysis. 
Research Questions and Hypotheses 
I will use the following research questions to guide my investigation. 
RQ1: Among Black patients newly diagnosed with NSCLC and reported to SEER 
between 2004 and 2011, do the proportions of NSCLC stage (I, II, III and IV) differ 
significantly between AFBB and AMBB patients? 
RQ2: Among Black patients diagnosed with early stage (I, II) NSCLC and reported to 
SEER between 2004 and 2011, does the proportion of AFBB patients who underwent 
surgery differ significantly from the corresponding proportion of AMBB patients?  
RQ3: Is there any significant difference in the proportion of AFBB NSCLC (stages I, II, 
III and IV) patients treated with radiation to the corresponding proportion of AMBB 
patients, reported to SEER from 2004-2011? 
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RQ4: Among Black early stage (I, II) NSCLC patients reported to SEER between 2004 
and 2011, does the proportion of AFBB patients who received neither surgery nor 
radiation differ significantly from the corresponding proportion of AMBB patients? 
The null hypothesis is that between the African-born and American-born Black 
populations living in the U.S., there are no differences in their NSCLC stage at diagnosis 
and the type of treatment they receive for the years 2004-2011. This retrospective study 
will utilize secondary analysis of quantitative data. With funding from the National 
Cancer Institute (NCI) the SEER program has created cancer registries around the United 
States that cover about 28% of the national population. These authoritative data sources 
provide data with variables that include the cases’ age, sex, date of birth, place of birth, 
race, geographic area, cancer type, and year of diagnosis are collected and submitted to a 
unified database maintained by SEER (National Cancer Institute, 2013a, 2013b, and 
2013c).  
Theoretical Framework 
I will draw from Ecological Theory which says that the ecology involved in 
human development describes that science which deals with the growing human’s 
exposure or active engagement in the properties of the changing living environment, as 
well as their larger interconnecting settings (Bronfenbrenner, 1979).  The environment in 
this context involves the immediate as well as the wider society that include 
governmental policies, culture and economic structures, that shape the growing person’s 
psychology, social and biological development (Bronfenbrenner, 1979, p. 21).  
Researchers have shown that adverse childhood experiences lead to increased risk for 
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lung cancer (Brown et al., 2010). To support this childhood experience risk factor,the 
effect of place of birth was shown to be a factor that influenced the receipt of breast 
cancer surgery when Chavan,Goodman, Jemal, & Fedewa (2014) compared U.S. resident 
breast cancer women born in 6 different countries. The theory held true after controlling 
for several covariates. Place of birth was the only variable that was linked to the observed 
outcome that showed within-race differences in which Foreign-born Asian women 
received less breast cancer surgery when compared to their counterpart American-born 
Asian women, as well as Non-Hispanic White women with OR of .76 at  95% and CI = 
.72 – 0.80. In another study the incidence rate of NSCLC is shown to be approximately 
35% higher for foreign born Asians than U.S. born Asians living in the State of 
California. This NSCLC incidence pattern by nativity is consistent with the populations’ 
tobacco smoking prevalence (Raz, Gomez, & Chang, 2008). Following these 
observations, whether place of birth influences the NSCLC stage at diagnosis as well as 
the type of treatment received by AFBB compared to their counterpart AMBB cases will 
be determined by the data analysis.  
Types and stages of lung cancer and treatment options.   
The SEER cancer staging manual requires lung cancer to be classified into the different 
types of tumors that are found. But, these different tumors fall under two main categories; 
the small cell lung cancer (SCLC) and the non-small cell lung cancer (NSCLC) (National 
Cancer Institute, 2013d, 2013e, and 2014f). The stage at diagnosis for lung cancer 
specifically applies to one type, the non-small-cell lung cancer (NSCLC) which 
constitutes a significantly higher incidence of all lung cancers cases (Mirsadraee, et al, 
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2012). It is detected at five major stages namely: occult or stage 0,  stage I, stage II, stage 
III and stage IV and thus reported as required by the SEER Program coding and staging 
manual, though the numbers diagnosed with stage 0 is usually too small to be considered 
in statistical analysis (National Cancer Institute, 2013d, and 2013e, and 2014f). 
Meanwhile, there are 5 major types of treatments possibilities for lung cancer and are 
namely: no treatment, surgery, radiation, chemotherapy and others to include 
experimental methods. Of these treatments, chemotherapy is only applied to SCLC 
though it is usually diagnosed at very advanced stage, unsuitable for surgery. Meanwhile 
NSCLC does not respond to chemotherapy and so is not reported to SEER. But, the 
earlier stages (I and II) are curable by surgery and radiation since they are localized. 
Meanwhile, the late stages (III and IV) are not suitable for surgery but do get radiation 
for palliative purposes (National Cancer Institute, 2014f).  
Significance of the study   
This study is basically an evaluation of the effect of birth place on the stage (I, II, 
III and IV) at which non-small cell lung cancer is diagnosed; and the type of treatment  
(no treatment, surgery or radiation therapy) received between U.S. resident AFBB and 
AMBB lung cancer patients. Between U.S and Africa, differences in the rate of 
screening, health services availability, treatment, follow-up care, and record keeping do 
exist. Therefore, it is best to compare data from samples of the two populations when 
they are living in the same environment where the opportunity for screening, treatment, 
care, record keeping and environmental conditions are more similar than when they are 
living in separate continents. According to the ecological theory on which this study is 
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based, these factors constitute the ecological factors that affect the wellbeing of an 
actively growing child (Bronfenbrenner, 1979) and so studying their effects on disease 
outcome in different populations can help detect where help is needed. 
Implications for Social Change 
This may help fulfill the goal of reducing cancer disparity for population groups 
as required by the Healthy People 2020 overarching goal (United States Department of 
Health and Human Services, 2010 and 2013). This study has a great potential for a social 
change. The study outcome could indicate whether there is a significant difference in the 
proportions of lung cancer stage at diagnosis, and treatment between of AFBB and 
AMBB NSCLC patients.  Also, it could be a basis for in-depth investigation to 
understand each group’s cultural, social, belief system, and ease of access to prevention 
education and treatment, all of which could be potential reasons why such differences 
were observed. This could aid in the development and implementation of interventions 
that may influence cultural, social and behavioral modifications that can in turn 
encourage early diagnosis for the population that is more at risk for late stage NSCLC 
diagnosis. This will help to appropriately achieve the goal of the Healthy People 2020, in 
the context of lung cancer that seeks to eliminate health disparities, gain health equity and 
maintain quality health for different population groups through the assessment of various 
demographics such as race/ethnicity and geography (United States Department of Health 
and Human Services, 2010, and 2013).  The study outcome will also be a key source of 
information to Africans seeking knowledge about African immigrant lung cancer 
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statistics as well as providing research opportunities to interested epidemiologists wishing 
to examine the risk factors that influence such within-race disparities.  
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Chapter 2: Literature Review 
  
In this chapter I will discuss research literature for lung cancer risk factors, incidence 
rates, treatment methods, mortality rates and stages at diagnosis for better understanding 
of the sample used and interpretation of the study findings. The review is subdivided into 
the literature search, epidemiological timeline of lung cancer, lung cancer risk factors, 
incidence and mortality  
 
Research Literature Search 
I searched for full-text research literature by using the major biomedical research 
databases PubMed Central, PLos One, the CDC’s Mortality Morbidity and Mortality 
Weekly Report database, and the National Library of Medicine. I also searched Google 
Scholar. The NCBI database includes titles such as Journal of Cancer Epidemiology, 
Journal of Clinical Oncology, Journal of Thoracic Oncology, CA: A Cancer Journal for 
Clinicians, Journal of the National Cancer Institute, , and Journal of Biomarkers & 
Prevention. I restricted my search to articles published within the past 5 years.  
I reviewed references in the articles I found for other relevant research. I found no 
primary research articles comparing lung cancer incidence and mortality and the stages at 
diagnosis as well as the treatment type received among AMBB and AFBB. Instead, the 
majority of the articles that I found concerned lung cancer risk factors; a few were 
epidemiological studies. I selected a total of 120 articles of much relevance to my 
research questions from the total of 8,803 that my general search returned. I further 
screened the 120 research articles for those with free access to the full text, and contacted 
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the Walden University Library for help with access to those with restricted access. 
Meanwhile I excluded some that were too recent and did not yet have any access from the 
literature review.  
Epidemiological Trend and Evidence of the Etiology: The Timeline 
Lung cancer and tobacco smoke.  Researchers began to describe malignant 
growth of the lung and bronchi and the possible etiology in the early 1900s. Adler (1912) 
reviewed hundreds of autopsy and pathology reports in Europe and the United States. He 
found an association between malignant growths of the lung and tuberculosis and  
suggested that subjects’ occupation and tobacco smoking might also be involved (Adler, 
1912). 
After Adler’s (1912) report, there were reports of noticeable increase in the 
incidence of lung cancer in England and Wales from 1921-1932 where the absolute 
number of lung cancer cases rose from 361 cases in 1921 to 2095 cases in 1932 for men 
and from 186 cases in 1921 to 680 cases in 1932 for women (Kenneway & Kenneway, 
1936). The death ratio for women increased from 1:1.94 in 1921 to 1:3.08 in 1934 
(Kenneway, & Kenneway, 1936). Clinically and statistically, Wynder and Graham (1950) 
demonstrated tobacco smoking as the major contributing factor to this rapid increase. In 
the cases that they analyzed, Wynder and Graham assessed individuals’ occupations, 
history of previous lung disease, hereditary components, and smoking habits.  
The researchers Wynder, & Graham (1950) found out that 98.7% of the 605 cases 
involved in their study were smokers. Following Wynder & Graham (1950) finding, Doll, 
& Hill (1950) conducted a study involving a much larger participants pool made up of 
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1731 lung cancer cases,  and control consisting of 1762 patients with cancer-of-other-
sites, respiratory and other diseases in England. The Doll, & Hill (1950) study 
participants were from varied residential cities but had similar access to medical care. 
Doll & Hill (1950) assessed their smoking history and habits in many different scenarios 
after eliminating sampling errors and interviewer bias. They considered estimated amount 
of tobacco that the subjects regularly and recently smoked before illness onset, the 
approximate maximum amount of tobacco smoked on a daily basis, and the approximate 
total smoked since starting to smoke. Doll & Hill (1950) then compared lung carcinoma 
patients and the study control group for each of these three scenarios. They found that 
heavy smokers made up a significantly larger proportion in the lung carcinoma group; 
26.0 % men and 14.6% women regularly smoked 25 or more cigarettes a day as 
compared to 13.5% men and 0% women in the control group. From their results, they 
concluded that carcinoma of the lung patients smoked the maximum amount for each 
scenario than the control, indicating that smoking might have played a role in causing 
their lung cancer (Doll & Hill (1950). Their study therefore showed that cigarette smoke 
causes lung cancer.   
Doll and Hill as well as other researchers continued to study the association 
between tobacco smoke and lung cancer, and in 1954 they initiated a prospective study 
involving 40,564 British mmedical ddoctors as the study subjects (Doll & Hill, 1954). 
They stratified the subjects during the baseline data collection into continuing smokers, 
ex-smokers, and never-smokers. They observed at intervals the subsequent changes in 
smoking habits and lung cancer mortality, as well as other diseases for the study subjects. 
20 
 
Lung cancer death rate increased as the amount of cigarette smoked per day increased 
after 29 months observation (Doll & Hill, 1954). The lung cancer death rate for 
nonsmokers was 0.00 per 1000 population, while for those who smoked at least 25g of 
tobacco or more daily was 1.14 per 1000 population (Doll & Hill, 1954). After 10 years 
observation, the death rate from lung cancer for continuing smokers doubled that for 
nonsmokers (Doll & Hill, 1964).  
In 1965, Hill compared their findings to that of the report of a study that was done 
several decades earlier involving scrotal cancer and its association to chimney sweeping 
(Waldron, 1983; Hill, 1965). He found a similarity in association between each disease 
and the environmental factors to which those patients were exposed (Hill, 1965). After 
elimination of chance occurrence, and despite these strong associations observed between 
lung cancer and smoking; and scrotal cancer and chimney sweep, to conclude that such 
environmental factors caused the diseases Hill (1965) pointed out a number of aspects of 
such associations that must be fulfilled. In his address to the Royal Society of Medicine 
during a meeting, Hill (1965) using the results of their tobacco smoking and lung cancer 
studies indicated that causation can only be concluded from  (1) the strength of the 
association between the disease and the factor in question in which case such an 
association must be in excess when compared to the disease association with other 
possible causes, (2) consistency of such an association, in which case the same result 
must be obtained if the study is repeated by different researchers at different times and 
locations, (3) specificity of association in which instance the association must be limited 
to a particular disease and population at a particular place, where no excess of the disease 
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is observed without the presence of the factor in consideration, exemplified by the results 
of the smoking and lung cancer study results (Doll, & Hill, 1964), (4) temporality of 
association in which case the exposure to the factor must occur before the onset of the 
disease; (5) Biological gradient exemplified by the fact that in their study, lung cancer 
death rate rose linearly with increase in amount of cigarette smoked; (6) plausibility; (7) 
coherence exemplified by the fact that the association between lung cancer and cigarette 
smoking has been coherent with the histopathology results for the disease in such 
patients; (8) experiment which he exemplified  by the fact that if cigarette smoking is 
eliminated, will the association between it and lung cancer reduce; and (9) analogy where 
the effect of similar factors leading to the same kind of association should be considered 
(Hill, 1965). These have since been known as the Bradford Hill Criteria for causation and 
are widely applied in epidemiological investigations of causality.  
During the 20th year Doll and Hill observation of the study population showed 
tobacco consumption had markedly reduced, and lung cancer death rate also reduced, but 
death rate from other diseases did not reduce accordingly (Doll, Peto, 1976). By the 40th 
year those who ceased smoking by middle age had substantially low risk of dying from 
lung cancer as compared to those who continued smoking (Doll, Peto, Wheatley, Gray, & 
Sutherland, 1994)  
With these revelations, studies focused on tobacco smoking have revealed its 
trend and relation to other diseases, including lung cancer incidence and mortality. In the 
United States, stratifying study cohorts by time periods as 1960s, 1980s and 
contemporary (2000s) in the comparison of those who smoked to those who never 
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smoked, showed the relative risks of death from lung cancer in women to be 2.73, 12.65, 
and 25.66 respectively, and  in men to be 12.22, 23.81, and 24.97 respectively (Thun, et 
al  2013). In 2009, the prevalence of cigarette smoking among adult US population 18 
years and older was 20.6% with prevalence of 23.5% for men and 17.9% for women 
(Centers for Disease Control and Prevention, 2010). For the 5 years period, from 2005-
2009, there was no significant difference in cigarette smoking prevalence which was 
recorded at 20.9% and 20.6% respectively for U.S adults 18 years and older (Centers for 
Disease Control and Prevention, 2010). 
Tobacco use is also common in Africa, exemplified by Ghana, a West African 
nation where studies have shown that smoking intention among the youths were 27.7% 
for those exposed to tobacco smoking commercials as compared to 19% for those not 
exposed to such commercials (Doku, Raisamo, & Wiium, 2012). Among Ghanaian 
adolescents 14-19 years old, tobacco smoking prevalence of 1.0% was lower when 
compared with the older adults 60-69 years with prevalence of 6.1% (Owusu-Dabo, 
Lewis, McNeill, Gilmore, & Britton, 2009, Table 2).  But, a later study showed the 
average daily smoking prevalence among the older adults estimated at 7.6%; meanwhile, 
the prevalence among men was higher at 11.3% as compared to female with 3.7% 
(Yawson, et al., 2013, Table 1). The countries, Rwanda, Uganda , Tanzania and Kenya, 
all located in Eastern Africa have the highest prevalence of cigarette smoking among men 
of 14.2%, 18.7%, 21.0%, and 22.9% respectively, with the lowest prevalence of 8.0% 




Lung cancer in never-smokers.  
Preexisting diseases as lung cancer risk factors. Despite the compelling 
evidence that has linked tobacco smoking to lung cancer incidence and mortality since 
the early 20th Century to contemporary times (Wynder, & Graham, 1950; Doll & Hill, 
1950, and Thun, et al, 2013), nonsmokers have other lung cancer risk factors too. These 
include environmental air pollutants and previous inflammatory lung disease (Samet,et al, 
2009, and Moldoveanu et al, 2009 ). Common among the inflammatory lung diseases 
which could also be seen in smokers are tuberculosis, emphysema, pneumonia and 
chronic bronchitis. But independent of tobacco smoking these conditions have been 
studied by the International Lung Cancer Consortium and shown that the relative risk for 
them to influence lung cancer are 1.48 (95% CI: 1.17-1.87), 2.44 (95% CI: 1.64 - 3.62), 
1.57 (95% CI: 1.22 - 2.01), and 1.47 (95% CI: 1.29 -1.68) respectively (Brenner, et al., 
2012). In a tuberculosis study cohort, 26.3 per 100,000 persons of patients with 
tuberculosis developed lung cancer; which is 10.9 times more, compared to the 2.41 per 
100,000 persons for non-tuberculosis patients who developed lung cancer (Yu, et al. 
2011). Another preexisting disease, HIV infection, is also a risk factor for lung cancer 
with an incidence relative risk of 1.7 (95% CI: 1.5 to 1.9)  after 37,294 HIV positive U.S 
Veterans and 75,750 uninfected controls, composed of about 50% non-Hispanic African 
Americans and 40% non-Hispanic Whites were followed for 5.8 years in a prospective 
cohort study (Sigel, et al., 2012). 
Environmental Air pollutants. Apart from preexisting diseases, chronic and acute 
exposure to some ambient air pollutants increases the risk for lung cancer (Turner, et al., 
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2011). One such air pollutant is silica and those exposed to it have a lifetime risk of 
0.51% for lung (Liu, et al., 2013). Nitrogen oxides derived from traffic is also associated 
with lung cancer with incidence relative risk (IRR) of 1.30 (95% CI: 1.05–1.61), 
(Raaschou-Nielsen, et al., 2011). 
Incidence and mortality. In South Africa, for the general population, the annual 
lung cancer mortality did not significantly change as it only minimally decreased from 
24.3 per 100,000 population in 1995 to 23.8 per 100,000 population in 2006  (Bello, 
Fadahun, Kielkowski, & Nelson, 2011). But, by gender, for corresponding years, the rate 
increased for women from 10.8 per 100,000 populations to 13.4 per 100,000 populations, 
though it decreased minimally for men from 44.2 per 100,000 populations to 39.4 per 
100,000 populations (Bello, et al., 2011). However for the general South African 
population, there was a significant change for the 5 years’ time frame of 2000-2005 with 
an annual decrease of 129 deaths per 100,000 populations though from 1999-2006 there 
was a significant annual increase of 0.34 per 100,000 populations for women (Bello, et 
al., 2011).  
Even though 1 out of 4 men in the East African country of Malawi smoke tobacco 
(Msyamboza, et al., 2011), a study of cancer burden in the country revealed that the least 
common cancer was lung cancer, and it accounted for only 0.2% of the 18,946 new 
cancer cases that were registered from 2007-2010 (Msyamboza, et al., 2012). A 
retrospective study spanning 15 years (1993-2007) identified 1,882 registered lung cancer 
cases in the North African nation of Tunisia which accounted for 10.9% of all the cancers 
registered during that period for the general population, but it contributed for 21.7% of all 
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cancer cases registered for men, and 1.4% for women (Missaoui, et al. 2011). The trend 
for lung cancer in Tunisia during the study period decreased significantly by - 6.5% (95% 
CI: -12.9% to - 0.2%), (Missaoui, et al. 2011).  
In a comparison of U.S non-Hispanic Black and White population aged 20 to 39 
from 1992-2006 the death rate from lung cancer per year decreased by 3.6% in white men 
and 7.9% in Black men, meanwhile, the decrease was 1.9% in White women and 4.8% in 
Black women (Jemal, Center, & Ward 2009).  There has been a marked reduction in the 
prevalence of tobacco smoking in the United States, more so for women and men of the 
West with average of 33.3% and 28.5% respectively while the smallest decrease is in the 
Midwest with 20.3% and 18.6% respectively (Jemal, et al., 2011).  Yet, in most U.S. 
States, lung cancer mortality rates for White women have been on the rise except for 
California where there has been a decline (Jemal, et al., 2012).  
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Chapter 3: Research Method 
 
In this chapter I will discuss the study objectives, research questions, and hypotheses. I 
will also describe the study method to provide a clear understanding of the research 
questions and hypotheses, the methods that I will use to obtain the data, the sample size 
calculation and instrumentation, as well as the statistical test methods for the data 
analysis.  
Study Objectives  
Reflecting on this within-race study, as stated in the research questions below the 
objective is two folds. Firstly, the objective is to gather lung cancer data collected from 
2004-2011 for AFBB and AMBB; and secondly, to use the acquired data to answer the 
research questions (RQ) following the stated hypotheses (H0) and alternative hypotheses 
(H1). The populations in the study are AFBB and AMBB who have been diagnosed as 
having NSCLC, and recorded in the SEER database. 
Research Questions, Hypotheses, and Alternative Hypotheses. 
I used the following research questions to guide my investigation: 
RQ1: Do the proportions of NSCLC stage (I, II, III and IV) in the SEER database 
for 2004-2011 differ between AFBB and AMBB patients? 
H01: There is no significant difference between the proportion of AFBB and 
AMBB diagnosed with NSCLC by stage (I, II, III and IV) and reported to SEER between 
2004 and 2011. 
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H11 There is a significant difference between the proportion of AFBB and AMBB 
diagnosed with NSCLC by stage (I, II, III and IV) and reported to SEER between 2004-
2011. 
RQ2: Among Black patients diagnosed with early stage (I, II) NSCLC reported to 
SEER between 2004-2011, does the proportion of AFBB patients who underwent  
surgery differ from the corresponding proportion of AMBB patients? 
H02: There is no significant difference between the proportion of AFBB early 
stage (I, II) NSCLC who underwent surgery and the corresponding proportion of AMBB 
patients that were reported to SEER between 2004-2011 
H12: There is a significant difference between the proportion of AFBB early stage 
(I, II) NSCLC who underwent surgery and the corresponding proportion of AMBB 
patients reported to SEER between 2004-2011 
RQ3: Is there a significant difference in the proportion of AFBB NSCLC (stages 
I, II, III and IV) patients treated with radiation to the corresponding proportion of AMBB 
patients, reported to SEER from 2004-2011? 
H03: The proportion of AFBB NSCLC (stages I, II, III and IV) patients treated 
with radiation differs from the corresponding proportion of AMBB patients, reported to 
SEER from 2004-2011. 
H13: The proportion of AFBB NSCLC (stages I, II, III and IV) patients treated 
with radiation differs from the corresponding proportion of AMBB patients, reported to 
SEER from 2004-2011. 
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RQ4: Among the early stage (I, II) NSCLC patients reported between 2004 and 
2011, does the proportion of AFBB patients who received neither surgery nor radiation 
differ significantly from the corresponding proportion of AMBB patients? 
H04: The proportion of AFBB early stage (I, II) NSCLC patients who received 
neither surgery nor radiation does not differ significantly from the corresponding 
proportion of AMBB patients, reported between 2004-2011. 
H14: The proportion of AFBB early stage (I, II) NSCLC patients who received 
neither surgery nor radiation differs from the corresponding proportion of AMBB 
patients, reported between 2004-2011; there is no significant difference in their 
proportion 
Research Population and Setting. 
 Based on my research questions and hypotheses, I limited eligibility of 
participants to patients who are Black and who were born in the United States or an 
African country or region. I excluded cases with unknown values for age, gender, stage at 
diagnosis, marital status, country of birth, radiation, and surgical treatment methods.  
Sample Size Determination. For this retrospective study, I determined the 
sample size using the Open Epi software calculator. I was interested in analyzing both 
male and female AFBB and AMBB cases. I based my sample size on a number of risk 
ratios (1.2, 1.5, and 1.75), a 95% CI, and the chance of detecting a meaningful outcome 
or the conventional statistical power for the study at least 80% (Fosgate, 2009). From 
information gathered from the Georgia Comprehensive Cancer Registry (GCCR), one of 
the SEER Program Registries, the ratio of AFBB lung cancer cases to AMBB lung cancer 
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cases is approximately 1:20. I used this ratio in the Open Epi software calculator for the 
“Ratio of unexposed to exposed” in the sample size calculation. For the pair of sample 
size calculation done, the percent of exposed with outcome is assumed at four possible 
values being 20%, 30%, 40%, and 50%; and the risk ratio at three different levels being 
1.2, 1.5 and 1.75. I used these figures in order to generate a wide range of eligible cases 
within which to choose the best sample size. Table 1 shows the sample size ratio for 
AFBB to AMBB patients with lung cancer. The ratio ranges from a low of 15:293 to a 
high of 850:16984. 
 
Table 1  Sample Size Ratios for Lung Cancer AFBB to AMBB Subjects 
% Unexposed with 
outcome RR=1.2   RR=1.5   RR=1.75 




















50     207/4121   33/669   15/293 
Note. Assumptions: power = 80%, two sided type error = 0.05 
RR is Risk ratio 
 
This AFBB to AMBB ratio of 1:20 calculated using the original sample presents a very 
wide size discrepancy which will inevitably influence a significant difference in the 
calculated proportions. Therefore, from the AMBB population a random sample shall be 
approximated to reduce the sample size ratio to 2 AMBB: 1 AFBB. In this process, 
patients’ age and gender which are confounding variables to the dependent variables shall 
be used to determine the sampling method for selecting the AMBB study sample. One of 
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two possible methods shall be used depending on the outcome of the preliminary 
population age and gender proportion comparisons for the two groups. If the population 
age and gender proportions comparisons yield a significant difference, between AFBB 
and AMBB, then from the unsorted AMBB original population, a number of cases that 
double the number of AFBB shall be selected from the top of the list. A second method 
of sampling if the preliminary population age and gender proportions comparison for 
AFBB and AMBB do not yield any significant difference will be purposive sampling. In 
this case 2 AMBB subjects shall be matched to 1 AFBB for all the AFBB subjects, by 
age and gender.    
SEER data source. The required secondary data variables for this study are all 
included in the SEER primary data information collected, which fall into 3 categories: (1) 
Cancer identification which include the primary site, stage, diagnostic procedure and 
date; (2) patient demographics to include the race, gender, age, and birth place, but void 
of personal identifiers; and (3) NSCLC disease treatment and outcome of the patients 
(National Cancer Institute, 2014b).    
Ethical consideration. For the SEER Program, patient confidentiality is highly 
respected during primary data collection. The gathering, reporting and accessing of the 
data are guided by specific laws, and are only allowable to eligible individuals (National 
Cancer Institute, 2014c). Furthermore, personal identifiers are coded before any 
transmission is done (National Cancer Institute, 2014c). Thus, the data for this study shall 
contain assigned or coded identities for each patient, rather than specific patient’s 
identifiers. To further protect the patients’ privacy, during abstracting of the lung cancer 
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data for this study, the SEER database shall be accessed following stipulated guidelines 
and permission from the SEER Program.  According to the SEER Program website, 
among all the primary data information collected, some basic ones such as cancer type 
and stage, date of cancer diagnosis, race, sex, age, type of treatment, and the date and 
status of last follow up are readily available to be abstracted (National Cancer Institute, 
2014d). Among these available information those appropriate to create the NSCLC study 
frequency data shall include the Black race cases, the year of diagnosis, sex, age, place of 
birth, treatment received, and marital status. The country of birth shall be decoded, and 
for those born in Africa, selection shall go by names of specific countries as well as the 
African Region (Northern, Southern, Middle, Eastern and Western Africa). For those 
born in the United States, all the SEER’s State-of-birth codes (National Cancer Institute, 
2014e) shall be recoded to the one code assigned to the country of birth as the United 
States of America (U.S.A.); then the SEER’s Government Services Administration codes 
for African Country of Birth (National Cancer Institute, 2013, and National Cancer 
Institute, 2014e). These abstracted data shall be   presented in a table, void of personal 
identifiers; and, being a secondary data analysis, there shall be no direct contact with the 
involved subjects. 
Statistical Analysis of Data  
For the data, the total number of NSCLC cases will serve as the subjects under 
study. Then, the data analysis shall be performed using the Statistical Package for the 
Social Sciences (SPSS) software (IBM Corporation, 2014). The statistical test to answer 
each of the four questions RQ1 through RQ4 will be the Chi-square test; and each p-
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value obtained compared to the alpha (0.05) to determine whether or not to reject the null 
hypothesis. This statistical test is suitable because each of the questions involves the 
difference between 2 groups only. The categorical independent variables is place of birth 
of Black race (represented by AFBB and AMBB), and the dependent variables are the 
stage-at-diagnosis of NSCLC; and the type of treatment received. The assumption here is 
that for each of the research questions, the 2 sets of samples are random and independent; 
and that the 2 populations from which the 2 groups, AFBB and AMBB NSCLC cases are 
derived are normally distributed.  It is also assumed that the test is going to be a 2-tailed 
test, meaning that there will be two rejection regions, one on each tail of the assumed 
normal distribution. This software comparison of the 2 groups’ proportions using the Chi 
square test will yield the p (or 2-tailed significance) values from which the 2 samples 
proportions differences can be interpreted by comparison to the critical p-value. Other 
possible predictors of the outcome under study include age, and marital status which can 
be possible confounding variables. For any of the Chi square tests that show a significant 
difference between the two groups, a logistic regression analysis shall be performed. For 
this test, the study subjects’ ages gender and the marital status shall be used as covariates 
to the place of birth.  
Study Limitations.  The potential limitations to this study will include but not 
limited to missing data due to unclassified cases by place of birth, inability to control for 
other relevant covariates such as culture, preexisting health condition, and type of 
healthcare system involved, lack of data collected for the duration of stay either in the 
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United States or country of birth for the AFBB population and duration of prior out-of-




Chapter 4: Results  
Introduction to data analysis and Results 
In this chapter, I present quantitative analyses of the NSCLC cases in order to 
profile the two study groups (AMBB and AFBB patients) and enable comparisons of 
their demographic characteristics, stage at diagnosis, and treatments. I matched the 
AMBB cases to the AFBB on their age and gender. I used a specific statistical tool and 
techniques to investigate the research questions and hypotheses and to predict the 
treatment type received. I also used logistic modeling. I performed the descriptive 
statistics for both samples prior to and after the matching process.  Furthermore, after 
descriptive, Pearson’s chi-square are used to test the study’s four hypotheses and the chi-
square value and the p-value are used to make decisions regarding the hypotheses. In 
order to make a decision to either accept or reject the null hypotheses, I compared the 
obtained p values to the alpha value of 0.05. Then, I estimated the binary logistic 
regressions to investigate which factors best predicted surgical and radiation treatment. 
Finally, I have presented a summary of the results at the end of the chapter. 
Data Acquisition and Recoding. I used the SEER.STAT software to query the 
data from the SEER-18 Registries database. The data query process was not 
straightforward due to the large number of differential codes used for the cancer 
histologic types and stages. I sought help from SEER by phone call and I asked for a 
complete list of the codes and for help in transferring the queried dataset from the SEER 
database into an Excel spread sheet. With the queried dataset, I recoded the age ranges, 
marital status, surgical therapy, radiation therapy, the country of birth to align with the 
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study questions. There were 135 AFBB and 25,139 AMBB. I eliminated 16 AFBB and 
2846 AMBB cases because of missing values. This process yielded 119 AFBB and 22293 
AMBB eligible cases using my study criteria, as outlined in Chapter 3. I then 
recategorized participants using 10-year intervals. Table 2 shows the age distribution of 
the cases. It excludes the 0-29 years old age group since that range had no AFBB cases. 
My recoding produced 5 age categories: 30-39 years, 40-49 years, 50-59 years, 60-69 
years, and >69 years. To provide more simplicity than that provided by SEER, I recoded 
marital status into four categories: single, married, Divorced, and Widowed. I classified 
the NSCLC stages at diagnosis as “Early Stage” (to include stages I and II) and “Late 
stage” (to include stages III and IV). Also, I dichotomized the therapy types received 
were surgery and radiation of which surgical therapy to “Yes”, if any of the 24 different 
types of surgical procedures reported was received, and “No” if none of the 24 different 
types was received. In the same way, I dichotomized radiation therapy to “Yes” to 
incorporate any of the various forms of radiation procedures received, and “No” if no 
form of radiation treatment was received. I renamed birth country as United States for 
AMBB patients and Africa for AFBB patients. This categorization was simpler and easy 
to understand the different groups and variables. 
Sampling of Data. Among the 135 AFBB and 25139 AMBB SEER cases for 
2004-2011, 16 AFBB and 2846 AMBB cases were missing some values. I eliminated 
these cases from the study dataset, which left 119 AFBB and 22293 AMBB NSCLC 
cases for the study sample. This left a study cohort with very large population ratio 
difference. I then considered a 1 AFBB to 2 AMBB sampling to reduce the sample size 
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difference and eliminate statistical differences that the large size difference would 
influence. In this case, I considered age and gender as the prime confounding variables 
and I used them for the match. Thus, I compared the age and gender distribution for 
AFBB and AMBB prior to the sampling, in order to determine if there were any age and 
gender distributions differences between the two groups prior to sampling. 
Age distribution prior to sampling AMBB study subjects. For the 5 age groups 
comparison, the result of the analysis is presented in Table 2 below.  
Table 2  Age Distribution for AFBB and AMBB Study Subjects 
Age (Years) 
                 Birth country     
         AMBB         AFBB p value   
30-39 139 (1%)  7 (6%)   0.00* 
 40-49  1572 (7%) 12 (10%) 0.2 
 50-59  5229 (24%) 38 (32%)   0.03* 
 
60-69 7100 (32%) 43 (36%) 0.32 
 > 69 8253 (37%) 19 (16%)    0.00* 
 Total 22293 (100%) 119 (100%)     
 
Note. Percent values were rounded. 
*p < 0.05 
Table 2 shows that there is a significant difference in age categories. Of the five age 
categories, three are significantly different between the AFBB and AMBB. AFBB 
patients were comparatively younger than the AMBB patients.   
Gender distribution prior to sampling AMBB study subjects. The result of 
gender distribution is presented in Table 3 below. It shows that the gender distribution 
between AMBB and AFBB patients was not significantly different.  
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Table 3  Gender distribution for all AFBB and prior to sampling AMBB study subjects  
                Gender 
Birth Country (USA or Africa) 
    
AMBB AFBB p-value   
 
Female 9089(41%) 59(50%) 0.05 
 
Male 13204(59%) 60(50%) 0.05 
 
Total 22293(100%) 119(100%) 
    
 
Note. Percent values were rounded. 
*p < 0.05  
Conclusively, for the before sampling test for age and gender distribution, the analysis 
found that the age distribution was significantly different between AMBB and AFBB 
cases prior to the sampling. But, for gender, the distribution was not significantly 
different. Table 3, shows that for AFBB the gender was 50% male and 50% female; 
while for AMBB the gender was 59% male and 41% female; this difference in gender 
distribution was not statistically significant. Random sampling for this study was then 
performed based on this result. Due to the low frequency count of 119 for AFBB I made 
a decision to include all 119 in the study. I did the sampling following the results of the 
age and gender distribution tests. From the non-ordered original 22293 AMBB data I 
selected the first 238 so as to provide 2 AMBB for each of the AFBB study subjects. I 
entered the study cohort consisting of 119 AFBB cases and 238 AMBB cases into SPSS 




Marital Status of the NSCLC cases. After recoding the marital status for this 
study sample as “single”, “married”, “divorced” and ‘widowed”, I computed the NSCLC 
disease frequency and percentages by marital status and presented the results in Table 4. 
Among the AFBB patients, 25% were single, while 24% of AMBB were single, and there 
is no significant difference between the two groups considering the single status.  
However, about 35% of AMBB cases were married, while 57% of the AFBB were 
married, this shows the proportion of AFBB cases that were married are higher, and there 
is a significant difference in proportion for married cases between AFBB and AMBB 
patients (p < 0.05).  
Table 4  Marital Status of AMBB and AFBB Subjects 
  
  
Birthplace (Africa or 
USA)  
  
  AMBB AFBB p-value 
 
Single 57(24%) 30(25%) 0.78 
     
Marrital  Status Married 82(35%) 68(57%) 
       
<0.05* 
     
 
Divorced 54(23%) 8(7%) <0.01* 
     
 
Widowed 45(19%) 13(11%) 0.05 
     Total 
 
238(100%) 119(100%) 
          
Note. Percent values were rounded. 
*p < 0.05 
Table 4 also shows that for AFBB, about 7% were divorced while for AMBB 23% were 
divorced patients. This indicates that the proportion of divorced AMBB patients is 
considerably higher compared to AFBB, and these proportions are significantly different 
(p < 0.05) as shown in Table 4. Finally, 11% of the AFBB patients were widowed and 
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19% of AMBB were widowed, and these proportions were not significantly different as 
shown on Table 4. 
NSCLC Stage at diagnosis. The NSCLC stage at diagnosis by birth place is 
presented in Table 5. Here, for AMBB patients 25% of the patients were at early stage, 
while for AFBB it was 24%. 
Table 5  NSCLC Stage at diagnosis by birth place (Africa or USA) for study subjects 
  
Birth place (Africa or USA)    

















      
 
Note. Percent values were rounded. 
Critical value: p > 0.05 
Also, 75% of the AMBB patients were diagnosed at late stage, while 77% of AFBB were 
at late stage.  The test of proportion for the NSCLC diagnosis at late stage shows that 
there is no significant difference between AMBB and AFBB patients as presented on 
Table 5. 
 
Surgical Treatment. The patients received two types of therapies, surgery and 
radiation. Table 6 illustrates the information regarding surgical therapy of the study 
subjects data set. As presented, 29% of the AFBB patients received surgical therapy, 
whereas 20% of the AMBB patients had surgical therapy as treatment, and these 
40 
 
proportions are significantly different (p < 0.05). Furthermore, as presented on Table 6, 
the proportion of AFBB patients that did not have surgery compared to the corresponding 
proportion of AMBB patients were significantly different (p < 0.05). The same 
conclusion applies to the proportions AFBB and AMBB that received surgical therapy (p 
< 0.05)  as shown on Table 6.  
Table 6  Surgical therapy by birthplace (Africa or USA) for study subjects 
 
         
Birth place         




191(80%) 84(71%)      0.04* 
 
  
     
Yes  
47(20%) 35(29%) 0.04* 
 
  
     
Total 
 238(100%) 119(100%)  
 
 
        
Note. Percent values were rounded 




Radiation Treatment. Table 7 shows that among AMBB patients 50% did not 
receive radiation therapy, compared with a corresponding 63% of AFBB patients. 
Statistically, these proportions are significantly different (p<0.05). Additionally, 37% of 
the AFBB patients received radiation therapy compared with a corresponding 50% of the 




Table 7  Radiation therapy by birthplace (Africa or USA) for study subjects 
 
  
Birth place (Africa or USA)     























          
Total 
      238(100%)   119(100%) 
 




Note. Percent values were rounded 




Hypotheses Testing.  
Based on the four research questions (RQ), the null hypothesis (H0) and alternative 
hypotheses (H1) for each corresponding RQ were formulated in order to objectively 
answer the questions. The alpha or predetermined level of statistical significance in this 
study was 0.05 to which all the p-values were compared to determine whether or not to 
reject the null hypothesis. In each case, I used the Chi-square test of independence to 
determine which hypothesis to accept and which to reject. The hypotheses test results are 
discussed in this section. 
In order to answer RQ1 and judge the hypotheses objectively, I applied the 
Pearson Chi-Square Analysis. Table 8 presents the expected and observed counts for each 
category of NSCLC stage for the AFBB and AMBB patients. I assessed the difference 
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between the observed count and expected counts and then calculated the p-value for each 
proportion. The result of Pearson Chi-Square Analysis is also presented in Table 8. 
 
Table 8  Pearson Chi-Square to assess the difference in NSCLC Stage at Diagnosis for 
AMBB and AFBB patients 
 
  
Birth place (Africa or USA)  
 








60(25%) 28(24%) 0.72* 
Expected 
Count 
58.7      29.3 
 




 178(75%) 91(77%) 0.72* Count 
Expected 
Count 
179.3      89.7 
 
   
 
 
Total Count 238(100%)     119(100%)   
 
Note. Percent values were rounded  
Pearson Chi-Square, X
2
 = 0.1206 
Degree of freedom = 1 
*Critical Value:  p > 0.05 
 
The result of the Pearson Chi-Square test indicates that there is no significant difference 
between the proportion of AFBB and AMBB diagnosed with NSCLC by stage (early and 
late) and reported to SEER from 2004-2011.  
To answer the RQ2 and assess the hypotheses objectively, I applied the Pearson 
Chi-Square Analysis. Table 9 is the contingency table which presents the expected and 
observed counts for each category by NSCLC early stage for the AFBB and AMBB 
patients who underwent surgery. 
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Table 9  Pearson Chi-Square to assess the differences between AMBB and AFBB patients 
diagnosed with early stage NSCLC who received surgical therapy 
 
  








28(47%) 6(21%) 0.02* 
No Expected Count  23.2            10.8   
 
       
  32(53%)    22(79%) 0.02* 
 
Count 
Yes Expected Count 36.8 
            
           19.7  
     
     
Total Count 60(100%)      28(100%)   
 
Note. Percent values were rounded. 
Pearson Chi-Square, X2 = 5.129 
Degree of freedom = 1 
*Critical Value:  p < 0.05 
 
Table 9 shows that there is a significant difference between the proportion of AFBB 
diagnosed with early stage (I, II) NSCLC and the corresponding proportion of AMBB 
patients who underwent surgery (p < 0.05). This means that the null hypothesis is 
rejected and the alternative hypothesis is accepted. As a whole, for surgical therapy as 
shown in Table 9, the proportion of AFBB patients who underwent  surgery differs from 
the corresponding proportion of AMBB patients (p < 0.05). AFBB patients were found to 
be more likely to have received surgical therapy compared with AMBB patients. 
To objectively answer RQ3 by assessing the hypotheses, I applied the cross-tab 
Pearson Chi-Square tests, first to those that were diagnosed at the early as well as the late 
stages and then to the overall disease stages at diagnosis, early and late combined. 
Amongst the patients diagnosed with NSCLC at the early stages, there was a significant 
44 
 
difference in the receipt of radiation therapy (p <0.05) between AMBB and AFBB. The 
proportion of AMBB patients (37%) that received radiation treatment was higher 
compared with the corresponding proportion of AFBB patients (14%) as shown on Table 
10. But, for those diagnosed at the late stages of the disease, there was no significant 
difference in the proportion of AMBB (55%) that received radiation therapy when 
compared with the corresponding proportion of AFBB patients (44%) as shown on Table 
11. When I compared the two groups for radiation treatment for the overall disease stages 
at diagnosis, early and late combined the result of the analysis is summarized and 
presented in Table 12. This Table 12 shows that per the Chi-Square analysis, the null 
hypothesis is rejected since the proportion of AFBB NSCLC (stages I, II, III and IV) 
patients treated with radiation therapy does differ significantly from the corresponding 




Table 10  Pearson Chi-Square to assess the difference in radiation therapy between 




Birthplace (Africa or 
USA) 








38(63%) 24(86%) 0.03* 
Expected Count 42.3 19.7   
       
Yes 
Count 22(37%) 4(14%) 0.03* 
Expected Count 17.7 8.3   
       
 
Total Count 60(100%) 28(100%)  
            
 
Note. Percent values were rounded. 
Pearson Chi-Square, X2 = 4.594 
Degree of freedom = 1 
*Critical Value:  p < 0.05 
 
Table 11 Pearson Chi-Square to assess the difference in radiation therapy between 
AMBB and AFBB patients diagnosed at late stage NSCLC 
  
Birthplace (Africa or 
USA) 







Count 80(45%) 51(56%) 0.08* 
Expected 
Count 
86.7 44.3   
       
Yes 
Count 98(55%) 40(44%) 0.08* 
Expected 
Count 
91.3 46.7   
       
  Total Count  178 100%)     91(100%)   
Note. Percent values were rounded. 
Pearson Chi-Square, X
2
 = 2.97 
Degree of freedom = 1 
*Critical Value:  p > 0.05 
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Table 12 Pearson Chi-Square to assess the difference in radiation therapy between 
AMBB and AFBB patients for all stages (Early and Late) 
 
  







Count 118(50%) 75(63%) 0.02* 
Expected Count 128.7 64.3   
       
Yes 




Expected Count Table 119.3 54.7 
 
       







Note. Percent values were rounded. 
Pearson Chi-Square, X2 = 5.77 
Degree of freedom = 1 
*Critical Value:  p < 0.05 
 
  
As presented in Table 12, among AMBB patients 50% did not receive radiation therapy, 
compared to a corresponding 63% of AFBB patients. Statistically, these proportions are 
significantly different (p < 0.05) as shown on Table 12with the corresponding 50% of the 
AMBB patients; and this difference was found to be statistically significant (p < 0.05). 
AMBB patients were more likely to receive radiation therapy at all the stages (I, II, III 
and IV) of the NSCLC than AFBB patients.  
For research question 4 (RQ 4), I queried the data and obtained a sample with 
total of eight early stage (I, II) NSCLC patients who received neither surgery nor 
radiation for both AFBB and AMBB. This was composed of 1 AFBB and 7 AMBB cases 
as shown in the Appendix. The attempt to use any statistical tools to test the hypothesis 
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was unsuccessful. Therefore, the hypotheses could not be tested and so the research 
question was left unanswered.  
Logistic Regression Analysis  
In modeling the relation between treatment types and demographic variables in 
relation to country of birth of the patients, I conducted the analysis for both surgical and 
radiation treatment. I used the variables available on the SEER database that are possibly 
responsible for influencing the receipt of surgery or radiation therapy as a treatment 
choice for the analysis. These include age, gender, marital status, country of birth (Africa 
or USA), and the stage at diagnosis for the NSCLC. For both surgery and radiation 
treatments the regression results are discussed in the sections below. 
Surgery treatment prediction. I performed a logistic regression analysis to 
ascertain the effect of age, gender, marital status, country of birth, and stage at diagnosis 
for the NSCLC in predicting the probability of a patient receiving surgery as treatment. In 
this case, the dependent variable is the surgery, dichotomized into “No Surgery” and 
“Surgery”. In the SPSS data analysis software I coded “No Surgery” as “1” and Surgery 
as “2”. Meanwhile, I coded the independent variables as follows: age of the patient at 
diagnosis (5 categories), gender (Female =1, Male =2), Marital Status (single = 1, 
married = 2, divorced = 3 and widowed = 4), Country of birth (AMBB = 1, AFBB = 2), 
and Stage at diagnosis (1= Early, 2 = Late). The result of the model is presented in 


















Age -0.279 0.156 1 0.075 0.757 0.557 1.028 
Gender -0.335 0.309 1 0.278 0.716 0.391 1.31 
Marital 
Status 
0.023 0.163 1 0.89 1.023 0.743 1.408 




0.663 0.326 1 0.042 1.94 1.024 3.677 
Constant 3.992 1.084 1 0 54.156 
  
                
Note. Description of table labels 
Model χ2 = 99.86, p<0.05 
Mode df = 5 
Pseudo R2 = 0.369 
N = 357 
 The Beta (un- standardized) represents the coefficients for the independent variables.  
S.E. is the standard error of the beta values;  
Df is the degree of freedom,  
Sig. is the p-value to show the significance of the independent variables in the model,  
Exp (B), is the Odds Ratio (OR) 
The logistic regression model was statistically significant (p < 0.05). The model 
explained 36.9% of the variance (R
2
) in surgical treatment for the NSCLC. 
In this model, stages at diagnosis and country of birth (USA or Africa) have significant 
influence on the model (p < 0.05). In the model, the most important variable turns out to 
be the stage at diagnosis which has a negative influence on the chance of a patient 
receiving surgery, (OR (AFBB/AMBB) = 0.06; 95%  CI  0.032-0.11) as shown on Table 
13. This indicates that for one unit increase in stage variable (Early stage, to Late stage) 
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here would be a 0.06 times reduction in the probability for a patient to receive surgery. In 
other words, if the stage goes from early to late, there would be 94% reduction in the 
likelihood of having surgery. This implies that late stage patients rarely ever have surgery 
as a treatment choice, which is as expected, considering the guidelines or 
recommendations for NSCLC treatment (National Cancer Institute, 2015; and National 
Comprehensive Cancer Network, 2015). Also in this model, country of birth (USA or 
Africa) has a positive beta value (OR (AFBB/AMBB) = 1.94; 95% CI 1.02-3.68) as 
shown on Table 13. This means that AFBB patients would receive surgery about 1.94 
times more compared to AMBB patients. 
       The summary of this regression analysis shows that the stage at diagnosis is one 
important factor in determining if a patient will receive surgical treatment, with surgery 
most likely to happen at early stage of NSCLC than at late stage. Furthermore, AFBB 
patients are more likely to receive surgery compared to the AMBB patients. 
Radiation treatment prediction. I performed another logistic regression analysis 
to determine the effect of age, gender, marital status, country of birth, and the disease 
stage in predicting the probability of a patient receiving radiation as treatment.  In this 
case, the dependent variable is radiation treatment, dichotomized as “No radiation”, and 
“radiation”, respectively coded in SPSS as “0” and “1”.  I entered the independent 
variables, age (with 5 categories), gender (1 = Female, 2 = Male), Marital Status (single = 
1, married = 2, divorced = 3 and widowed = 4), Country of birth (AMBB= 1, AFBB = 2) 
and Stage (1= Early, 2 = Late) in the model. The result summary of the model is 
presented in Table 14 below.  
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95.0% CI for 
EXP(B) 
Lower Upper 
Age 0.019 0.113 1 0.88 1.019 0.817 1.272 
Gender 0.082 0.225 1 0.71 1.086 0.699 1.688 
Marital 
Status 
0.087 0.116 1 0.46 1.091 0.869 1.37 
Stage  
at diagnosis 




-0.544 0.246 1 0.03 0.581 0.358 0.941 
Constant -1.512 0.845 1 0.07 0.22 
  
                
Note. Description of table labels 
Model χ2 = 20.17   
Model df = 5 
n = 357 
The logistic regression model was statistically significant, p < 0.05.  
The model explains 7.3% of the variance in surgery probability based on the independent 
variables.  
The Beta (un- standardized) represents the coefficients for the independent variables.  
S.E. is the standard error of the beta values;  
df is the degree of freedom,  
Sig. is the P-value to show the significance of the independent variables in the model,  
Exp (B) is the Odds Ratio (OR) 
  
In this particular model in predicting radiation treatment probability, Stage at diagnosis 
and Country of birth (USA or Africa) are the variables that are significant as predictors 
with the respective p-values of 0.00 and 0.03. The other 3 variables; age, gender, and 
marital status are not statistically significant in predicting radiation treatment. The most 
important variable in this model is the “Stage at diagnosis”, which has a positive 
influence on receiving radiation as a form of treatment. Correspondingly, for early to late 
stage, there would be 2.58 times increase in the probability of receiving radiation as 
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treatment. This implies that late stage patients would have 2.58 times higher probability 
of receiving radiation treatment than early stage. This is an expected result given the 
NSCLC treatment guidelines or recommendations that early stage NSCLC patients 
should get radiation therapy only when they cannot have surgery, or be treated by 
radiation therapy in combination with surgery for clinical trial purposes (Howington, 
Blum, Chang, Balekian, & Murthy, 2013). Meanwhile, the late stage disease patients are 
to receive radiation therapy without any restrictions (National Cancer Institute, 2015). 
Additionally, the country of birth (USA or Africa) of the patients in the model shows that 
AMBB patients will receive radiation therapy more compared to AFBB patients. The 
regression analysis for radiation treatment prediction indicates that, for radiation therapy 
the patients are only dependent upon the stage of NSCLC and country of birth. Other 
demographics included in the model (age, gender, marital status) were not predictive of 
radiation treatment. Conclusively, at the late stage of NSCLC, there is very low 
probability of receiving surgery; meanwhile there is higher probability for radiation 
treatment, which is an expected result, following the NSCLC treatment guidelines or 
recommendations (National Cancer Institute, 2015; and National Comprehensive Cancer 
Network, 2015).  
Results summary to the research questions.  
Research Question 1. The results indicate that statistically there is no significant 
difference in the proportions of AFBB and AMBB patients for the NSCLC stage (early 
and late) at diagnosis as shown in Table 8.  
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Research Question 2. The results show in Table 6 that the proportions of AFBB 
patients who underwent surgery differ significantly from the corresponding proportion of 
AMBB patients (p < 0.05), the AFBB patients were more likely to have surgical 
treatment compared to AMBB patients. There are no previous studies available that 
compared these two populations; therefore this result cannot be compared to any other 
and so must be interpreted with caution.  
Research Question 3. The analysis found a significant difference in the 
proportion of AFBB NSCLC (stages I, II, III and IV) patients treated with radiation to the 
corresponding proportion of AMBB patients (p < 0.05) as shown on Table 12, where the 
AMBB patients were more likely to receive radiation therapy compared to AFBB 
patients.   
Research Question 4. Among the early stage (I, II) NSCLC patients reported to 
SEER between 2004 and 2011, does the proportion of AFBB patients who received 
neither surgery nor radiation differ significantly from the corresponding proportion of 
AMBB patients? I did not perform any statistical analysis for this research question 
because the subgroup sample counts were very low as shown in Appendix.  
Regression model for surgery. In predicting surgery as a treatment, the stage at 
diagnosis of the NSCLC is the most significant predictor followed by the country of birth 
(USA or Africa). Patients diagnosed with early stage NSCLC have a higher probability of 
receiving surgery as a treatment than those diagnosed at late stage of the disease, which is 
as expected, given the recommendations for treatment of NSCLC patients (National 
Cancer Institute, 2015; and National Comprehensive Cancer Network, 2015). In addition, 
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The AFBB patients were younger than AMBB patients as shown on Table 2, and the 
AFBB patients had a higher probability of getting surgery than AMBB patients (OR 
[AFBB/AMBB] = 1.94; 95% CI 1.02-3.68) as shown on Table 13. 
Regression model for radiation. The variable that seems to influence radiation 
treatment more is the stage at diagnosis of the patient. In this case with diagnosis at late 
stage, the NCSLC patients are administered radiation therapy more, compared to the 
early stage which is an expected outcome due to the guidelines or recommendations for 
which treatment is suitable for what stage of the disease (National Cancer Institute, 2015; 
and National Comprehensive Cancer Network 2015). Also, the country of birth (USA or 
Africa) is an important predictor; here the AMBB patients are more likely to receive 
radiation therapy compared to AFBB patients. (OR [AFBB/AMBB] = 0.58; CI 0.36 – 
0.94) as shown on Table 14. Other demographics tested showed no influence on 
predicting the radiation therapy receipt.  
Summary 
In this chapter, I used descriptive, hypotheses and regression models to analyze the 
NCSLC patient data. The study used all of the AFBB and a sample drawn from the 
AMBB population for the analysis to obtain the statistical tests results. I obtained the 
AMBB sample using a random sampling method after doing a comparative age and 
gender proportions of the two groups void of those with missing data values. The study 
found significant differences between the proportions of AMBB and AFBB NSCLC 
cases (p < 0.05) in 3 out of the 5 age categories, as shown in Table 2. But, the difference 
in gender distribution was not statistically significant as shown in Table 3. The study also 
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modeled the relationship for different treatment methods (surgery and radiation) and 
found that the stage at diagnosis and country of birth (USA or Africa) are important 




Chapter 5: Discussion, Conclusions, and Recommendations 
Strengths and Weaknesses 
This study’s strength lies in comparison of NSCLC patients who are of the same 
race, AFBB and AMBB. In conducting this study, I strove to increase the knowledge 
about within-race similarities and differences in relation to where NSCLC patients were 
born, in Africa or in the United States. I did not have access to some data including 
socioeconomic status and health insurance, which are important factors for lung cancer 
disease outcome (Elchoufaniz, et al, 2013). Thus, one limitation to this study is that I was 
not able to test the effects of these factors on patients’ stage at diagnosis and treatment 
they received. In addition, the sample size was limited by the number of AFBB that were 
diagnosed with NSCLC from 2004-2011. The low sample size for AFBB was further 
affected by the number of cases with missing dependent variable data which I eliminated 
from the study. I ignored the probability sample that I initially calculated for this study of 
the size discrepancy between the two groups, AFBB (n= 135) and AMBB (n = 22293). 
Meanwhile, from the total AMBB population, I performed an approximate random 
sampling to obtain the study sample size and thus preserving the representativeness of the 
AMBB selected study sample. Thus, it made the study more valid given the assured 
representativeness of the samples selected from the total AMBB (n = 22293) group. The 
lack of adequate number of sample for each group of early stage (I and II) NSCLC 
patients (AFBB = 1 and AMBB = 7) as shown on Appendix A that received neither 





Using the chi-square tests and the logistic regression analysis, I found no 
significant difference in the proportions of AFBB and AMBB patients at early and late 
stages of NSCLC diagnosis. However, the proportions of AFBB patients who underwent 
surgery differed significantly from the corresponding proportion of AMBB patients (p < 
0.05; see Table 6). I also found a significant difference in the proportion of AFBB 
NSCLC (stages I, II, III and IV) patients treated with radiation as compared to the 
corresponding proportion of AMBB patients (p < 0.05). But, the difference between 
AFBB and AMBB patients that received neither surgery nor radiation could not be 
calculated because of low sample counts for the subgroups.  
The logistic regression analysis for predicting treatment receipt showed that 
AFBB patients had a slightly higher probability to receive surgery compared to AMBB. 
This study found that the AFBB patients were younger than AMBB as shown on Table 2. 
The logistic regression analysis (OR [AFBB/AMBB]) = 1.94; 95% CI 1.02-3.68) means 
that the AFBB patients had a higher probability of having had surgery as shown on Table 
13, where the stage at diagnosis and the country of birth (USA or Africa) were the best 
predictors of a patient to receive surgical therapy. Since the AFBB patients are younger, 
their diagnosis would be earlier. With the AFBB patients being younger implies that the 
AMBB patients were older. This analysis showed that the AMBB patients were more 
likely to have received radiation treatment compared with AFBB patients where the Stage 
at diagnosis and Country of birth (USA or Africa) with respective p-values of 0.00 and 
0.03 were the best predictors for a patient to receive radiation therapy as shown on Table 
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14. Literature search revealed that there are no existing previous studies that compared 
these two populations with respect to NSCLC stage at diagnosis and the treatment 
received. Thus it is difficult to make a comparison of this study outcome to previous 
study literature in that same context. But, in the context of treating the disease as it relates 
to the age and the disease stage at diagnosis for the general population of NSCLC 
patients, this study outcome is similar to results obtained by a number of studies. In one 
study that analyzed SEER lung cancer in general by comparing the older patient 
population to the younger ones the result showed that elderly patient population received 
surgical treatment only at half the rate at which younger patient population did 
(Owonikoko, Ragin, Belani, Oton, Gooding, Taioli, et al., 2007). In another study that 
analyzed data from a regional cancer registry, 80.2% of younger patients had surgery for 
NSCLC, compared with 55.8% of the elderly; while radiation treatment was administered 
more often in the elderly patients (30.5%) compared with 14.0% of the younger patients 
(Hillner, McDonald, Desch, Smith, Penberthy, & Retchin, 1998).  
These findings are all consistent with expectations based upon NSCLC treatment 
guidelines or recommendations (National Cancer Institute, 2015; National 
Comprehensive Cancer Network, 2015). Researchers analyzing SEER data have found 
that stage at diagnosis is similar for all age groups, from the young through the elderly 
(Owonikokoet al., 2007). Their findings validate the finding in this study that even 
though AFBB and AMBB patient populations are significantly different in their ages, the 




Even though I did not find any significant differences among AFBB and AMBB NSCLC 
patients for the stage at diagnosis, I recommend that further lung cancer studies involving 
comparisons of these two groups be performed with a much larger sample of AFBB 
patients. This would provide better insights to whether any within race differences do 
exist between the two groups with a bigger sample size, essential for efficient planning 
the prevention and management of the disease.  
Other covariates that include profession, socioeconomic status, and health insurance 
status were not available in the SEER database for all the years, 2004-2011 for both 
groups. Since all the patients in the SEER database are de-identified for confidentiality 
purposes, it was not possible to do any datalink to obtain information on these 
unavailable covariates from institutions that diagnosed them with NSCLC. I could not 
measure the effects of these variables on predicting the probability for the receipt of 
surgery or radiation therapy as a treatment choice. Therefore, I recommend that 
researchers conduct further studies with a larger AFBB sample. Future researchers may 
consider conducting original research in partnership with diagnostic institutions instead 
of using a secondary data source such as the SEERS dataset. In doing so, they may be 
able include these covariates to test their effects in predicting the probability of a patient 
receiving surgery as treatment.  
Conclusively, while there was no significant difference between AFBB and AMBB for 
the stage at diagnosis of the NSCLC, there were significant differences in each type of 
treatment receipt.  The two subgroups involved in this study are both of the same race 
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and are resident in the same country and so race and current country of residence are not 
likely causes for this observed treatment differences. Given that there were no significant 
gender differences before the comparisons were done and that I controlled for age by 
doing the approximate random sampling to obtain the study sample size, it means that 
gender and age differences are not likely cause for the observed significant difference in 
treatment receipt.  While other likely cause for such significant difference are the same 
and others have been controlled for, the country of birth was not controlled for in terms 
of their early childhood experiences and so might have been the reason why such a 
difference in treatment receipt is observed. Therefore, the ecological theory can be used 
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